We were discussing the prognosis because usually we are very focused on predictors of worse prognosis, but probably we should be looking more into the trajectories of patients. We know there are different phenotypes of cerebral venous thrombosis patients, patients that have isolated intracranial hypertension usually have a much better prognosis. And then patients that have brain lesions, about half of the patients will have parenchymal brain lesions...
We were discussing the prognosis because usually we are very focused on predictors of worse prognosis, but probably we should be looking more into the trajectories of patients. We know there are different phenotypes of cerebral venous thrombosis patients, patients that have isolated intracranial hypertension usually have a much better prognosis. And then patients that have brain lesions, about half of the patients will have parenchymal brain lesions. And these are patients indeed that may deteriorate, may have more a malignant profile. And probably we should be looking more into how to predict the deterioration of these patients and how to prevent this worsening from happening more than just predicting worse prognosis at the end based on the baseline characteristics. Although we do have several studies, large studies already on tools to help us to predict the prognosis like the SI2NCAL2C score that was published recently from the International CVT Consortium.
Then we were also looking into acute treatment. Of course, a very big question, and probably one of the next frontiers, is to understand better who could be the patients that can improve from endovascular treatment, benefit from endovascular treatment. So this probably requires us to think about how to select these patients better. And this can be related with imaging, with, again, predicting better who are these patients that may worsen. And also in terms of the technique, we need to look more into what are the best techniques to perform endovascular treatment in CVT, what are the safer options, and also in terms of the profile of the recanalization, what is the level of recanalization that we need to improve prognosis, and what are the best techniques to come with this better recanalization. So overall, this is an important question and definitely a next frontier for cerebral venous thrombosis. Then we were also discussing, still in the acute treatment, decompressive surgery. Decompressive surgery, we have shown in the DECOMPRESS2 study, prospective study on decompressive surgery in CVT, that these patients, only about 10%, will have a Rankin scale 4 to 5 after surgery. Either the patients die, still one third of the patients die despite surgery. This is definitely also something we have to look into, how to prevent death in this group of patients. But also the ones that survive. We see that in the long term, up to 12 months, there’s an improvement and most of the patients will be independent. So definitely this is a treatment that we have now to look more into the implementation to make sure about the pathways and the access to decompressive surgery, that there’s awareness that these patients should be treated, even if they are comatose or they are deteriorating, they will benefit from surgery quite likely and not being left with them. So I think implementation is probably the next frontier in this regard, more than further showing the evidence that decompressive surgery is life-saving and is associated with good outcomes in these patients.
So concerning the secondary prevention, that is definitely also one of the next frontiers in cerebral venous thrombosis. So patients have an indication to continue anticoagulation, full anticoagulation for a period after the thrombotic event, of course. We have shown recently, we have presented at ESOC 2026 the results of the EXCOA-CVT cluster randomized trial, where we compared the short-term policy of six months and the long-term policy of 12 months in patients without an indication for definite anticoagulation for long-term treatment. And indeed, we couldn’t see a difference in terms of significant difference in terms of recurrence for the overall population, meaning that we now usually use the six months duration of anticoagulation after an event. However, for the future, probably we have to look into specific populations and really try to understand who are the patients that may benefit from different types of policies in terms of secondary prevention. And finally, all these studies and all this progression in terms of the evidence in cerebral venous thrombosis only can be done in collaborations and multicenter collaborations since this is a rare disease. So definitely a very important frontier is to keep collaboration worldwide and to continue to develop consortiums and networks to help us to improve the quality of evidence for cerebral venous thrombosis patients in the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.